Navigation Links
HIV Vaccine Failure Still Brings Insights
Date:11/13/2008

Researchers say lessons learned might one day lead to vaccine that works

THURSDAY, Nov. 13 (HealthDay News) -- The latest attempt to develop an AIDS vaccine has failed, but researchers report that they've still gained insight into how to make the next one more effective.

"It's raised a whole new set of questions that are going to be really important to answer to get us to a successful vaccine," said Dr. Susan P. Buchbinder, lead author of a study published online Nov. 13 in The Lancet. "We couldn't have raised them or even anticipated them before doing this study."

Among other things, researchers now know that they need to understand the role of the foreskin in HIV transmission because uncircumcised men who were vaccinated had a higher rate of infection, said Buchbinder, director of the HIV research section at the San Francisco Department of Public Health.

Scientists have long dreamed about creating a vaccine to prevent transmission of HIV, the virus that causes AIDS. But the disease has turned out to be extremely stubborn. Among other things, HIV's ability to mutate into new forms has made it difficult to develop a vaccine that can keep up with all the changes.

Two experimental HIV vaccines have made it to testing in large numbers of people, but both failed to work.

In their study, Buchbinder and her colleagues looked at the results of testing of the second vaccine, which was developed by Merck & Co. Some of the results have already been released.

Researchers enrolled 3,000 HIV-negative people from North America, South America, the Caribbean and Australia in the study. Some received doses of the vaccine while others got a placebo.

The researchers found that 4.6 percent of those who received the vaccine became infected with HIV, compared to 3.1 percent of those who didn't get the vaccine.

It wasn't clear if the difference was statistically significant, but researchers did find that uncircumcised men were at higher risk of getting infected.

This suggests that scientists need to better understand how the foreskin affects the immune system's response to HIV, Buchbinder said.

Infection rates were also higher among those who had developed immunity to a virus that causes colds. This is important because scientists got the HIV vaccine to enter the body by piggybacking on a weakened bit of the same type of cold virus.

The vaccine can't cause HIV, and the weakened cold virus can't cause a cold, Buchbinder said.

But, there's another possibility, she said. The increase in infection rates among the two groups -- uncircumcised men and those who had immunity to the cold virus -- could be purely due to chance. Or some other factors could be at play.

The failure of the Merck vaccine "profoundly affected the HIV-vaccine development field," Dr. Merlin L. Robb, of the U.S. Military HIV Research Program, wrote in a commentary accompanying the study.

"We have learned that future HIV vaccines will need to generate stronger, broader or different types of immune responses in order to be effective," he said in an interview.

More information

Learn more about HIV vaccine research from the U.S. Centers for Disease Control and Prevention.



SOURCES: Susan P. Buchbinder, M.D., director, HIV research section, San Francisco Department of Public Health; Merlin L. Robb, M.D., U.S. Military HIV Research Program, Rockville, Md.; Nov. 13, 2008, The Lancet, online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Consumer Reports Survey: Nearly Half of Adults Wont Get Flu Vaccine, Citing Poor Excuses Like I Dont Get Sick
2. New Vaccines for Adults: Which do you Need? From Harvard Medical School
3. Research indicates need for effective HPV vaccine for women and men and a simple HPV screening test
4. Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients
5. Therapeutic vaccines
6. Minor shift in vaccine schedule has potential to reduce infant illness, death
7. Pakistan introduces vaccine to prevent top child killer
8. Flu Vaccine Could Prevent 357,000 Deaths in Pandemic
9. Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award
10. New intranasal influenza vaccine triggers robust immunity with significantly less antigen
11. When It Comes to Flu, the More Who Get Vaccine, the Better
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
HIV Vaccine Failure Still Brings Insights
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading ... today announced that Kyle Allain has joined the company as Vice President and ... operations, including provider, payor and managed care solutions. , A seasoned executive ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health ... anxiety levels in people with addiction who are served by MAP’s patient engagement ... wearable device that monitors heart and breath rates to identify anxiety levels and ...
(Date:4/24/2017)... ... ... As a former supermodel known for her timeless beauty, Joan Severance knows ... is that she put all the words in her new book, "Manifest Your Mate: ... and sparkling sense of humor have inspired her to write a book on how ...
(Date:4/24/2017)... , ... April 24, 2017 , ... Donna Parker, L. ... she has not found any of them to be very practical. She wanted to ... and easily make changes in their health. It prompted her in writing “ A ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “Learning to Use ... navigate life. “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues” is ... various nonprofits, former Chairman of the Board of Directors for CONTACT USA, and former ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: